Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 16/20 | 0.77 |
| ▸ | MAPK7 | Q13164 | 14/20 | 0.77 |
| ▸ | DCLK1 | O15075 | 12/20 | 0.77 |
| ▸ | BRD4 | O60885 | 8/20 | 0.77 |
| ▸ | NUAK1 | O60285 | 1/20 | 0.74 |
| ▸ | BRDT | Q58F21 | 2/20 | 0.70 |
| ▸ | TNK2 | Q07912 | 2/20 | 0.69 |
| ▸ | TNK1 | Q13470 | 2/20 | 0.69 |
| ▸ | DCLK2 | Q8N568 | 2/20 | 0.69 |
| ▸ | GAK | O14976 | 1/20 | 0.69 |
| ▸ | PLK4 | O00444 | 1/20 | 0.59 |
| ▸ | PI4KA | P42356 | 1/20 | 0.59 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.59 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.59 |
| ▸ | RPS6KA2 | Q15349 | 1/20 | 0.59 |
| ▸ | RPS6KA1 | Q15418 | 1/20 | 0.59 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL616711 | 0.93 | LRRK2 (0.67) | LRRK2MAPK7DCLK1BRD4NUAK1 | |
| SCHEMBL619514 | 0.93 | LRRK2 (0.74) | LRRK2MAPK7DCLK1BRD4NUAK1 | |
| SCHEMBL17721085 | 0.93 | LRRK2 (0.74) | LRRK2MAPK7DCLK1BRD4NUAK1 | |
| SCHEMBL16982789 | 0.89 | LRRK2 (0.67) | LRRK2MAPK7DCLK1BRD4NUAK1 | |
| SCHEMBL17839842 | 0.89 | MAPK7 (0.71) | LRRK2MAPK7DCLK1BRD4NUAK1 | |
| SCHEMBL619716 | 0.87 | NUAK1 (0.95) | LRRK2MAPK7DCLK1BRD4NUAK1 | |
| SCHEMBL619352 | 0.87 | BRD4 (1.00) | LRRK2MAPK7DCLK1BRD4NUAK1 | |
| SCHEMBL16065750 | 0.86 | NUAK1 (0.82) | LRRK2MAPK7DCLK1BRD4NUAK1 | |
| SCHEMBL10098745 | 0.85 | MAPK7 (0.64) | LRRK2MAPK7DCLK1BRD4NUAK1 | |
| SCHEMBL617312 | 0.85 | MAPK7 (1.00) | LRRK2MAPK7DCLK1BRD4NUAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 104 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120040961-A1 | PYRIMIDO-DIAZEPINONE KINASE SCAFFOLD COMPOUNDS AND METHODS OF TREATING DISORDERS | DANA-FARBER CANCER INSTITUTE (US) | 2012-02-16 | — | — | US | claimed |
| US-12023385-B2 | Tunable endogenous protein degradation with heterobifunctional compounds | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2024-07-02 | — | — | US | disclosed |
| US-12023385-B2 | Tunable endogenous protein degradation with heterobifunctional compounds | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2024-07-02 | — | — | US | disclosed |
| EP-3256470-B1 | METHODS TO INDUCE TARGETED PROTEIN DEGRADATION THROUGH BIFUNCTIONAL MOLECULES | DANA FARBER CANCER INST INC (US) | 2023-07-26 | — | — | EP | disclosed |
| EP-3256470-B1 | METHODS TO INDUCE TARGETED PROTEIN DEGRADATION THROUGH BIFUNCTIONAL MOLECULES | DANA FARBER CANCER INST INC (US) | 2023-07-26 | — | — | EP | disclosed |
| US-11583586-B2 | Methods to induce targeted protein degradation through bifunctional molecules | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-02-21 | — | — | US | disclosed |
| US-11583586-B2 | Methods to induce targeted protein degradation through bifunctional molecules | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-02-21 | — | — | US | disclosed |
| EP-4119552-A1 | REGULATING CHIMERIC ANTIGEN RECEPTORS | Dana-Farber Cancer Institute, Inc. (US) | 2023-01-18 | — | — | EP | disclosed |
| CN-108350062-B | Targeted protein degradation to attenuate adverse inflammatory responses associated with adoptive T cell therapy | 达纳-法伯癌症研究所股份有限公司 | 2022-10-14 | — | — | CN | disclosed |
| EP-3331905-B1 | TARGETED PROTEIN DEGRADATION TO ATTENUATE ADOPTIVE T-CELL THERAPY ASSOCIATED ADVERSE INFLAMMATORY RESPONSES | DANA FARBER CANCER INST INC (US) | 2022-10-05 | — | — | EP | disclosed |
| US-20160176916-A1 | METHODS TO INDUCE TARGETED PROTEIN DEGRADATION THROUGH BIFUNCTIONAL MOLECULES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-06-23 | — | — | US | disclosed |
| US-20160176916-A1 | METHODS TO INDUCE TARGETED PROTEIN DEGRADATION THROUGH BIFUNCTIONAL MOLECULES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-06-23 | — | — | US | disclosed |
| US-20160122357-A1 | PYRIMIDO-DIAZEPINONE KINASE SCAFFOLD COMPOUNDS AND METHODS OF TREATING DISORDERS | DANA-FARBER CANCER INSTITUTE, INC. | 2016-05-05 | — | — | US | disclosed |
| US-20160122357-A1 | PYRIMIDO-DIAZEPINONE KINASE SCAFFOLD COMPOUNDS AND METHODS OF TREATING DISORDERS | DANA-FARBER CANCER INSTITUTE, INC. | 2016-05-05 | — | — | US | disclosed |
| US-9266890-B2 | Pyrimido-diazepinone kinase scaffold compounds and methods of treating disorders | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2016-02-23 | — | — | US | disclosed |
| US-9266890-B2 | Pyrimido-diazepinone kinase scaffold compounds and methods of treating disorders | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2016-02-23 | — | — | US | disclosed |
| US-9266890-B2 | Pyrimido-diazepinone kinase scaffold compounds and methods of treating disorders | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2016-02-23 | — | — | US | disclosed |
| US-20120040961-A1 | PYRIMIDO-DIAZEPINONE KINASE SCAFFOLD COMPOUNDS AND METHODS OF TREATING DISORDERS | DANA-FARBER CANCER INSTITUTE (US) | 2012-02-16 | — | — | US | disclosed |
| US-20120040961-A1 | PYRIMIDO-DIAZEPINONE KINASE SCAFFOLD COMPOUNDS AND METHODS OF TREATING DISORDERS | DANA-FARBER CANCER INSTITUTE (US) | 2012-02-16 | — | — | US | disclosed |
| US-20120040961-A1 | PYRIMIDO-DIAZEPINONE KINASE SCAFFOLD COMPOUNDS AND METHODS OF TREATING DISORDERS | DANA-FARBER CANCER INSTITUTE (US) | 2012-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120040961-A1 | PYRIMIDO-DIAZEPINONE KINASE SCAFFOLD COMPOUNDS AND METHODS OF TREATING DISORDERS | BRSK2, BRSK1, TAOK3 | LRRK2 364/4885MAPK7 263/4885DCLK1 480/4885 |
| US-11583586-B2 | Methods to induce targeted protein degradation through bifunctional molecules | CRBN, MDM2, MYCBP | LRRK2 1253/4885MAPK7 3496/4885DCLK1 1829/4885 |
| US-20160122357-A1 | PYRIMIDO-DIAZEPINONE KINASE SCAFFOLD COMPOUNDS AND METHODS OF TREATING DISORDERS | BRSK2, STK3, BRSK1 | LRRK2 340/4885MAPK7 253/4885DCLK1 453/4885 |
| US-12023385-B2 | Tunable endogenous protein degradation with heterobifunctional compounds | DBN1, MYCBP, PSMG3 | LRRK2 1995/4885MAPK7 4605/4885DCLK1 2364/4885 |
| US-20160176916-A1 | METHODS TO INDUCE TARGETED PROTEIN DEGRADATION THROUGH BIFUNCTIONAL MOLECULES | CRBN, MDM2, MYCBP | LRRK2 1253/4885MAPK7 3496/4885DCLK1 1829/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.